We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

114 hedge funds and large institutions have $58.6M invested in Karyopharm Therapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,238% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $89K

4% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 26

1% more funds holding

Funds holding: 113 → 114 (+1)

0.72% less ownership

Funds ownership: 4.33% → 3.61% (-0.72%)

27% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 33

48% less capital invested

Capital invested by funds: $113M → $58.6M (-$54.3M)

Holders
114
Holders Change
+1
Holders Change %
+0.88%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
24
Reduced
33
Closed
26
Calls
$1.19M
Puts
$89K
Net Calls
+$1.1M
Net Calls Change
+$1.09M

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$1.57M
2
Jane Street
Jane Street
New York
+$1.52M
3
KCM
Kennedy Capital Management
Missouri
+$1.32M
4
Millennium Management
Millennium Management
New York
+$1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$905K

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$6.93M
2
BlackRock
BlackRock
New York
-$5.83M
3
State Street
State Street
Massachusetts
-$2.02M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.33M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$755K
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
26
AQR Capital Management
Connecticut
$649K +$687K +41,480 +495%
ACM
27
Altium Capital Management
New York
$642K – – –
CSS
28
Cubist Systematic Strategies
Connecticut
$494K +$628K +37,932 New
SCM
29
Silverarc Capital Management
Massachusetts
$485K – – –
SCM
30
Superstring Capital Management
New York
$464K +$590K +35,632 New
Macquarie Group
31
Macquarie Group
Australia
$439K +$6.28K +379 +1%
BC
32
Birchview Capital
Vermont
$408K – – –
State Street
33
State Street
Massachusetts
$394K -$2.02M -122,132 -80%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$385K +$405K +24,458 +479%
YIH
35
Y-Intercept (HK)
Hong Kong
$357K +$454K +27,397 New
IC
36
Ikarian Capital
Texas
$355K – – –
Los Angeles Capital Management
37
Los Angeles Capital Management
California
$307K -$37K -2,234 -9%
Bank of America
38
Bank of America
North Carolina
$259K +$155K +9,384 +89%
Fidelity Investments
39
Fidelity Investments
Massachusetts
$254K +$21.4K +1,294 +7%
BCM
40
Bridgeway Capital Management
Texas
$229K +$82.8K +5,000 +40%
AI
41
Atom Investors
Texas
$227K +$19.3K +1,163 +7%
CC
42
Centiva Capital
New York
$177K +$225K +13,573 New
Morgan Stanley
43
Morgan Stanley
New York
$174K -$105K -6,318 -32%
DCM
44
DAFNA Capital Management
California
$167K – – –
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
$167K +$214K +12,945 New
Bank of New York Mellon
46
Bank of New York Mellon
New York
$144K -$354K -21,383 -66%
PAS
47
Point72 Asia (Singapore)
Singapore
$143K +$182K +11,021 New
ETC
48
Exchange Traded Concepts
Oklahoma
$141K -$55.7K -3,364 -24%
Citigroup
49
Citigroup
New York
$141K +$158K +9,540 +756%
HF
50
HRT Financial
New York
$128K +$163K +9,836 New
1
2
3 4 5

KPTI Hedge Fund Activity: Q2 2024 in Review

114 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2024, worth a combined $58.6M — down 48% from $113M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new KPTI positions and 26 closed out — a net gain of 1 holder — while 24 added to existing stakes and 33 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.57M. The largest seller was Avidity Partners Management, cutting an estimated $6.93M.

  • 114 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2024, up from 113 in Q1 2024.
  • Funds reported $58.6M of Karyopharm Therapeutics stock for Q2 2024, down 48% quarter-over-quarter.
  • 27 funds opened new Karyopharm Therapeutics positions in Q2 2024 and 26 closed out, a net change of +1 holder.
  • The largest Karyopharm Therapeutics buyer in Q2 2024 was Opaleye Management, an estimated $1.57M added.
  • The largest Karyopharm Therapeutics seller in Q2 2024 was Avidity Partners Management, an estimated $6.93M sold.

Based on aggregated 13F filings for Q2 2024.